Apellis Pharmaceuticals has been granted a patent for a method of treating chronic respiratory disorders and other chronic complement-mediated disorders. The method involves administering multiple doses of a complement inhibitor to the subject according to a specific dosing schedule. The complement inhibitor can be administered through various routes and includes a nucleic acid component. GlobalData’s report on Apellis Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Apellis Pharmaceuticals, Cyclosporin derivatives was a key innovation area identified from patents. Apellis Pharmaceuticals's grant share as of September 2023 was 33%. Grant share is based on the ratio of number of grants to total number of patents.
Method of treating chronic respiratory or complement-mediated disorders using complement inhibitor
A recently granted patent (Publication Number: US11712460B2) describes a method for treating chronic respiratory disorders or other chronic complement-mediated disorders. The method involves administering multiple doses of a complement inhibitor to the subject using various routes such as intravenous, intramuscular, subcutaneous, or respiratory. The dosing schedule requires that successive doses be administered at specific intervals based on the plasma concentration of the complement inhibitor.
According to the claims, the dosing schedule can be determined in three ways. First, the successive doses should be administered on average at least 3 weeks after the plasma concentration of the complement inhibitor decreases to no more than 10% of the maximum plasma concentration reached after the previous dose. Second, the doses can be administered at intervals such that the subject's complement activation capacity remains at least 50% of baseline for an average of at least 3 weeks between doses. Lastly, the doses can be administered at intervals equal to or greater than 10 times the terminal plasma half-life of the complement inhibitor when administered by the same route.
The complement inhibitor used in the method comprises a nucleic acid, specifically an RNAi agent such as a short interfering RNA that inhibits the expression of C3. Alternatively, the complement inhibitor can be a protease that degrades C3.
The patent also specifies the different routes of administration for the complement inhibitor, including intravenous, intramuscular, subcutaneous, and respiratory routes.
Overall, this patent provides a method for treating chronic respiratory disorders or other chronic complement-mediated disorders by administering multiple doses of a complement inhibitor using various routes of administration. The dosing schedule is based on the plasma concentration of the inhibitor and aims to maintain the subject's complement activation capacity. The use of nucleic acids or proteases as complement inhibitors adds to the potential therapeutic options for these disorders.
To know more about GlobalData’s detailed insights on Apellis Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
